Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17)

Phase II Clinical Trial

A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer
Trial Number: 05609578
Trial Status: Call Proj Mgr

Learn more about this clinical trial.

Participating Locations